var title_f6_55_7024="Kohler disease";
var content_f6_55_7024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kohler disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral and oblique views of the foot demonstrate flattening and sclerosis of the tarsal navicular. Evidence of progression is required to differentiate Kohler disease from a normal growth variant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7024=[""].join("\n");
var outline_f6_55_7024=null;
var title_f6_55_7025="Fotemustine: International drug information";
var content_f6_55_7025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fotemustine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Muforan (AR);",
"     </li>",
"     <li>",
"      Muphoran (AT, AU, BR, FR, GR, IL, IT);",
"     </li>",
"     <li>",
"      Mustoforan (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2528118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent (Nitrosourea)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2528119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To treat malignant melanoma",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2528181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week for 3 weeks, follow up 4-5 weeks after first dose (blood counts permitting): 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2528182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 208 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10463 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-115.25.216.6-89DD65BA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7025=[""].join("\n");
var outline_f6_55_7025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369786\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528118\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528119\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528181\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821170\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528182\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_55_7026="Milch technique for shoulder reduction";
var content_f6_55_7026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Milch technique for shoulder reduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arm is abducted and the physician's thumb is used to push the humeral head into its proper position. Gentle traction in line with the humerus is provided with the physician's opposite hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott C Sherman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7026=[""].join("\n");
var outline_f6_55_7026=null;
var title_f6_55_7027="Internal podalic version";
var content_f6_55_7027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Internal podalic version",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note use of long version gloves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.1078.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7027=[""].join("\n");
var outline_f6_55_7027=null;
var title_f6_55_7028="Echocardiogram instrumentation";
var content_f6_55_7028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Instrumentation of echocardiographic imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis plane of the left ventricle is obtained by placing the transducer on the chest wall, overlying the cardiac structures, directing a beam (broad shaded line) through the heart (upper row, left). As each structure is encountered it reflects ultrasound which is then detected by the instrument during its \"listening\" mode. These detected structures are displayed as a row of spike arranged according to their relative distances from the transducer; this is known as amplitude modulation or A-mode. The width of each spike at its base is proportional to the size of the structure creating it. When the object being imaged is viewed in real time, the spike will be seen to shift position. Since the A-mode display is not convenient for pattern recognition, its signal is modulated to brightness or B-mode. The height of each spike is expressed as dot brightness and its width as dot diameter. The dots, when played across a photosenstive strip chart or oscillographic display can leave a permanant paper or video tracing known as a time-motion mode record or M-mode echocardiogram. Various means of producing real time two dimensional images or sector scans are shown on the bottom row. A single beam of ultrasound is played back and forth through a sector; as the beam sweeps it leaves several thin lines of B-mode information. When viewed in video or digital format, these lines and dots are visually integrated and produce a real time tomographic cross section of information that precisely replicates an anatomic slice along plane.",
"    <div class=\"footnotes\">",
"     CW: chest wall; RVW: right ventricular wall; Sept: interventricular septum; AML: anterior mitral valve leaflet; PMV: posterior mitral valve leaflet; LVW: posterior wall of left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Norman H Silverman.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7028=[""].join("\n");
var outline_f6_55_7028=null;
var title_f6_55_7029="ECG complete HB with Mobitz type II";
var content_f6_55_7029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1102px;\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing complete heart block in a patient with syncopal episodes who previously had shown mobitz II type AV block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 75px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first two beats are paced. After the pacemaker is turned off, a normally conducted beat followed with a PR interval of 0.19 sec and a LBBB morphology. The next eight P waves fail to conduct and no lower pacemaker appears to assume control of the ventricles. Restarting the artificial pacemaker led to the QRS complex at the end of the rhythm strip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7029=[""].join("\n");
var outline_f6_55_7029=null;
var title_f6_55_7030="Lichen spinulosus";
var content_f6_55_7030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Lichen spinulosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circumscribed plaque with hyperkeratotic follicular papules on the abdomen of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7030=[""].join("\n");
var outline_f6_55_7030=null;
var title_f6_55_7031="Development of a metanephric excretory unit";
var content_f6_55_7031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Development of a metanephric excretory unit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrows, the place where the excretory unit (blue) establishes an open communication with the collecting system (yellow), allowing flow of urine from the glomerulus into the collecting ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler, T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7031=[""].join("\n");
var outline_f6_55_7031=null;
var title_f6_55_7032="Acute phosphate nephropathy";
var content_f6_55_7032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute phosphate nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Glen S Markowitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Mark A Perazella, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7032/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/55/7032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute phosphate nephropathy is a form of kidney injury that occurs following the use of bowel purgatives that contain oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    (OSP) and has been reported following the administration of sodium phosphate-containing enemas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. OSP was formerly sold without prescription under the brand name \"Fleet Phospho-soda\" (C.B. Fleet Inc.) or as a generic equivalent. OSP is currently available only by prescription in a pill form (Visicol, Osmoprep; Salix Pharmaceuticals). In both pill and liquid form, OSP is a hyperosmotic laxative that acts by drawing water into the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Although long used as a laxative, OSP began to be used as a purgative for colonoscopy in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/3\">",
"     3",
"    </a>",
"    ]. It is frequently given in favor of standard polyethylene glycol-based lavage solutions because of the smaller required volume, which results in better patient compliance and improved colonic cleansing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there have been multiple cases of OSP-induced acute kidney injury (AKI) with defining histologic features on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. This clinicopathologic entity has been referred to as acute phosphate nephropathy.",
"   </p>",
"   <p>",
"    In 2006, in response to published reports, the United States Food and Drug Administration (FDA) issued a warning regarding the potential for AKI in patients who received OSP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/12\">",
"     12",
"    </a>",
"    ]. The warning was incorporated into a consensus document on bowel preparation by the American Society of Colon &amp; Rectal Surgeons, the American Society of Gastrointestinal Endoscopy, and the Society of American Gastrointestinal &amp; Endoscopic Surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/13\">",
"     13",
"    </a>",
"    ]. In December 2008, the FDA required that a boxed warning be added to labeling of Visicol and Osmoprep, which are still available by prescription [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/14\">",
"     14",
"    </a>",
"    ]. At the same time, following the recommendation of the FDA, over-the-counter preparations that contain OSP were voluntarily withdrawn from the market by the manufacturer.",
"   </p>",
"   <p>",
"    This topic provides a review of the clinical features of acute phosphate nephropathy. AKI associated with an increased phosphate load has also been described in tumor lysis syndrome, especially with alkalinization of the urine by bicarbonate-containing intravenous fluids. Tumor lysis syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism underlying acute phosphate nephropathy most likely relates to a transient but potentially severe increase in serum phosphate coupled with volume depletion, both of which may occur following the administration of bowel purgatives that contain oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    (OSP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia occurs in a large number of patients following OSP ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ]. In one study, 28 percent of patients who underwent elective colonoscopy had serum phosphate concentrations greater than 8.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (normal range 2.5 to 4.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.8 to 1.5",
"    <span class=\"nowrap\">",
"     mmol/L))",
"    </span>",
"    following OSP administration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high rate of hyperphosphatemia following the use of OSP as a bowel purgative reflects the ingestion of a large amount of phosphate over a short period of time; this leads to a marked increase in phosphate absorption since the intestinal sodium-phosphate cotransporters that mediate absorption cannot be rapidly downregulated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until reports were published describing acute phosphate nephropathy, the recommended dose as a bowel preparation provided 11.6 grams of phosphorus within 24 hours, an amount that far exceeds the usual dietary intake of 1",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    Subsequent to reports of kidney injury, a phosphate dose reduction of 17 to 20 percent has been instituted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperphosphatemia is more likely to occur in patients with renal insufficiency, who have decreased excretion of phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/16,19-22\">",
"     16,19-22",
"    </a>",
"    ]. As a result, OSP is contraindicated in patients with clinically significant acute or chronic impairment in renal function.",
"   </p>",
"   <p>",
"    However, hyperphosphatemia also occurs in patients with normal renal function, as illustrated in a study of 70 patients with creatinine clearances greater than 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/16\">",
"     16",
"    </a>",
"    ]. After OSP administration, 37 percent had serum phosphate levels greater than 8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    In this study, there was a strong correlation between patient age and the degree of hyperphosphatemia, suggesting that age-related factors (including decreased total body water, abnormal bowel motility, enhanced GI absorption) unrelated to kidney function promote hyperphosphatemia. As a result, advanced age may increase the risk for the development of acute phosphate nephropathy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hyperphosphatemia is more likely to occur in patients who have impaired gastrointestinal motility, which leads to increased phosphate absorption. Gastrointestinal obstruction is a contraindication to the use of OSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nephrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which hyperphosphatemia causes kidney injury is not known, although hypotheses have been raised based on observed histology. The predominant (though not exclusive) finding on renal biopsy is widespread deposition of calcium phosphate in tubular lumina, tubular epithelia, and the interstitium. There is also evidence of tubular epithelial injury and inflammation. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One hypothesis to explain the pathogenesis is that transient hyperphosphatemia leads to an increased intratubular phosphate concentration, resulting in the precipitation and tissue deposition of calcium phosphate salts that cause luminal obstruction, direct tubular epithelial injury, and activation of the immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/19,23\">",
"     19,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although tubular injury is noted in all nephron segments, calcium phosphate deposition is limited to the distal tubule and collecting duct [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/24\">",
"     24",
"    </a>",
"    ]. The delivery of phosphate to these sites is enhanced by the decrease in proximal tubular phosphate absorption that occurs within minutes of OSP ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intraluminal calcium phosphate deposition is probably worsened by volume depletion, which often results from the OSP-induced osmotic diarrhea in the setting of reduced oral intake prior to the procedure. Conditions that cause effective volume depletion, such as heart failure and ascites, are contraindications to the use of OSP.",
"   </p>",
"   <p>",
"    True or effective volume depletion results in increased sodium chloride and water reabsorption in the proximal tubule. This effect combined with ongoing water reabsorption in the descending limb of the loop of Henle raises the calcium phosphate product within the tubular lumen in the fluid presented to the ascending limb and distal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/25\">",
"     25",
"    </a>",
"    ]. Volume depletion may also increase the adherence of calcium phosphate crystals to the distal tubule epithelium via an increase in surface expression of hyaluronan and osteopontin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are on angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) appear to be at increased risk for acute phosphate nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ACE inhibitors and ARBs worsen the prerenal state caused by OSP-induced volume depletion by promoting the loss of angiotensin II-mediated efferent arteriolar constriction, which reduces glomerular filtration. In addition, ACE inhibitors and ARBs decrease angiotensin II-dependent proximal tubule bicarbonate reabsorption, which leads to an increase in distal tubular bicarbonate concentration. The increase in intraluminal pH promotes precipitation of calcium phosphate crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chief pathologic characteristic of acute phosphate nephropathy is extensive deposition of calcium phosphate in the tubular lumina, within tubular epithelial cells, and, less commonly, in the peritubular interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/24\">",
"     24",
"    </a>",
"    ]. Calcium phosphate deposits are distinguished from calcium oxalate deposits by positive staining with the \"von Kossa stain\" and the absence of birefringence under polarized light (",
"    <a class=\"graphic graphic_picture graphicRef55578 \" href=\"UTD.htm?9/39/9848\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other findings observed on renal biopsy depend upon the elapsed time between OSP exposure and the time at which the biopsy was performed. Early biopsies show tubular degenerative changes similar to those seen in acute tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/24\">",
"     24",
"    </a>",
"    ]. These changes include luminal ectasia, cytoplasmic simplification, loss of brush border, shedding of cell fragments into the lumina, and enlarged nuclei with prominent nucleoli. The tubular degenerative changes and calcifications are accompanied by interstitial edema and mild to moderate interstitial inflammation that is not typically associated with significant tubulitis.",
"   </p>",
"   <p>",
"    In contrast, renal biopsies performed more than three weeks following OSP use show chronic changes including tubular atrophy and interstitial fibrosis. The tubular degenerative changes are less severe and more localized and resemble changes seen in repeat renal biopsies from patients with non-resolving acute tubular necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reliable data on the incidence of acute phosphate nephropathy in patients with previously intact renal function. A number of retrospective studies have examined this issue by evaluating the frequency or magnitude of reduction in estimated glomerular filtration rate at 6 to 12 months after the administration of bowel purgatives that contain oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    (OSP) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/27,28,31,32\">",
"     27,28,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, all of these studies are limited in a variety of ways including lack of confirmation of the diagnosis by renal biopsy. This is an important issue since many patients who develop AKI following OSP administration do not have acute phosphate nephropathy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Acute and reversible kidney injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study is an observational analysis of 9799 Department of Defense beneficiaries who underwent colonoscopy between 2002 and 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/31\">",
"       31",
"      </a>",
"      ]. AKI, defined as a greater than 50 percent increase in serum creatinine from baseline within one year following colonoscopy, was observed in 114 patients. After adjusting for putative risk factors, OSP was the strongest risk factor for AKI (risk ratio of 2.35, 95% CI 1.51-3.66).",
"     </li>",
"     <li>",
"      A retrospective case control study evaluated 2237 patients who had outpatient colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/28\">",
"       28",
"      </a>",
"      ]. AKI, defined as a 25 percent or a 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44.2",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      increase in serum creatinine over six months post-colonoscopy, was identified in 141 patients (6.3 percent). An association between OSP and AKI was only seen in patients who received an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, interpretation of this study is limited by the small sample size and the permissive definition of AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/33\">",
"     33",
"    </a>",
"    ]. When a stricter definition of AKI (which required an increase in creatinine of 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88.4",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    was employed, the number of cases of kidney injury fell from 116 to 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following potential risk factors for the development of acute phosphate nephropathy have been identified. However, since only the series from Columbia had biopsy confirmation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/8\">",
"     8",
"    </a>",
"    ], one cannot be certain how many of the patients with impaired renal function in other series had acute phosphate nephropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphate dosing &mdash; The degree of hyperphosphatemia is directly related to the total amount of administered OSP, and a greater degree of hyperphosphatemia is likely to increase the risk of acute phosphate nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/3,34-36\">",
"       3,34-36",
"      </a>",
"      ]. A wider interval between the administration of the two doses of OSP (ie, 24 versus 12 hours) is associated with a lesser degree of hyperphosphatemia and, therefore, is likely to be safer [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/19,33\">",
"       19,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic kidney disease &mdash; Reduced GFR increases the risk of hyperphosphatemia following OSP administration. A retrospective study on the safety of bowel preparations in patients with an estimated GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 found an adjusted relative risk of AKI for OSP-exposed patients of 12.6 relative to PEG-exposed patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/37\">",
"       37",
"      </a>",
"      ]. OSP is contraindicated in patients with a clinically significant impairment in renal function.",
"     </li>",
"     <li>",
"      ACE inhibitors and ARBs &mdash; In the series from Columbia, 14 of 21 patients with acute phosphate nephropathy were being treated one of these two agents [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/8\">",
"       8",
"      </a>",
"      ]. The increased risk conferred by these agents has been confirmed in observational studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &mdash; Advanced age has been identified as an independent risk factor in multiple studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/16,31,32,38\">",
"       16,31,32,38",
"      </a>",
"      ]. An absolute age at which the risk is increased has not been determined.",
"     </li>",
"     <li>",
"      Drugs &mdash; The use of diuretics, nonsteroidal antiinflammatory agents, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      have been suggested as possible risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/19,38\">",
"       19,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Female gender &mdash; The majority of reported cases of acute phosphate nephropathy have occurred in women [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/8,28\">",
"       8,28",
"      </a>",
"      ]. A possible contributing factor is that female subjects are generally smaller and have a lower GFR than men, but receive the same dose of OSP.",
"     </li>",
"     <li>",
"      Comorbid conditions &mdash; Hypertension and diabetes have been suggested as risk factors by several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/8,27,32\">",
"       8,27,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174443914\">",
"    <span class=\"h2\">",
"     Risk with sodium phosphate-containing enemas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute phosphate nephropathy also has been rarely reported following the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -containing enemas, although the majority of these reports have followed the use of excessive doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. One report highlights the occurrence of acute phosphate nephropathy following the use of the commonly recommended 250 mL dose of sodium phosphate-containing enemas in elderly patients. In this report, 11 elderly patients with a mean age of 80 years (range 61 to 89 years) developed AKI following the administration of Fleet enemas; of these, three individuals had received large doses of 500 to 798 mL and eight had received standard doses of 250 to 266 mL. Four patients had normal baseline renal function (defined as estimated GFR greater than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73) and seven had reduced renal function (estimated GFR between 25 to 57",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2). Although renal functional outcomes are not provided, five patients expired. Histologic confirmation of the diagnosis of acute phosphate nephropathy was available for a single patient in which tubular calcium phosphate deposits were found at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different clinical patterns of kidney injury have been described following the administration of bowel purgatives that contain oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    (OSP): an acute form that is reversible and may not represent acute phosphate nephropathy; and a delayed onset that is due to acute phosphate nephropathy and is generally irreversible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute and reversible kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, AKI occurs within hours of the administration of OSP. This presentation is mainly associated with excessive dosing of OSP or other risk factors for hyperphosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. AKI occurs in the setting of severe hyperphosphatemia and hypocalcemia leading to tetany, cardiac arrest, and in some cases, death. Patients who survive the immediate event typically return to normal or near-normal renal function. As a result, renal biopsy was not performed.",
"   </p>",
"   <p>",
"    It appears likely that the AKI in these patients was due to prerenal factors or acute tubular necrosis rather than acute phosphate nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute phosphate nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, acute phosphate nephropathy is characterized by increases in serum creatinine that occur in asymptomatic patients and are documented days to months following OSP administration. The serum phosphate and calcium concentrations are typically normal when kidney injury is discovered. The majority of reports of acute phosphate nephropathy have been confirmed by renal biopsy.",
"   </p>",
"   <p>",
"    The largest series on acute phosphate nephropathy is a retrospective review of biopsies processed by the renal pathology laboratory at Columbia University from 2000 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/8\">",
"     8",
"    </a>",
"    ]. This study identified 21 patients who had biopsy-confirmed acute phosphate nephropathy and a compatible history of OSP ingestion. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seventeen of the 21 patients were Caucasian, 17 were women, and the mean age was 64 years. Sixteen patients had a history of hypertension, and 14 of the 16 were taking either an ACE inhibitor or ARB. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mean baseline (within four months of the procedure) serum creatinine was 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88.4",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      In contrast, the mean value at the time of presentation with AKI was 3.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (345",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      at a median of one month after colonoscopy.",
"     </li>",
"     <li>",
"      The urinalysis was bland in 13 patients; hematuria was observed in three patients and pyuria in five patients. Twenty-four-hour protein excretion was less than 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in 13 of 14 patients in whom quantification was performed. In the seven other patients, urinalysis showed 0 to 1+ proteinuria on dipstick testing. Protein excretion exceeded 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in only one patient who had concurrent diabetic glomerulosclerosis on renal biopsy.",
"     </li>",
"     <li>",
"      Most patients appear to have taken OSP at the correct dose and in the absence of clear contraindications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At mean follow-up of 16.7 months, four patients progressed to end-stage renal disease and the remaining 17 patients had a decline in serum creatinine to a mean of 2.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (212",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    No patient returned to baseline renal function. Similar findings have been noted by others; complete recovery of renal function, if it occurs, appears to be rare event [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/41,44-46\">",
"     41,44-46",
"    </a>",
"    ]. In the Department of Defense study cited above, 16 percent of patients returned to their baseline serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7032/abstract/31\">",
"     31",
"    </a>",
"    ]. However, renal biopsies were not performed and some or many of these patients may have had acute tubular necrosis rather than acute phosphate nephropathy.",
"   </p>",
"   <p>",
"    Given the poor prognosis, identification of patients at risk and preventive measures are important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute phosphate nephropathy is suggested by the temporal association between AKI and the administration of bowel purgatives that contain oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    (OSP). However, some patients present late after the exposure with chronic kidney disease.",
"   </p>",
"   <p>",
"    The diagnosis of phosphate nephropathy is supported by a benign sediment on urinalysis and modest proteinuria. By definition, all patients with phosphate nephropathy should be normocalcemic, since hypercalcemia may also cause nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17081?source=see_link\">",
"     \"Nephrocalcinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no reports of the use of imaging to demonstrate nephrocalcinosis in acute phosphate nephropathy. As a result, the diagnosis can be confirmed only by renal biopsy, which may not be required in patients with AKI diagnosed shortly after using an oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    purgative. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the patient who presents days to months following colonoscopy with an elevated creatinine, minimal proteinuria, and a relatively bland urine sediment, the differential diagnosis includes acute and chronic tubular and interstitial diseases. These include acute and chronic forms of interstitial nephritis, ischemic and toxic forms of acute tubular necrosis, and myeloma cast nephropathy, to name a few. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a renal biopsy is obtained, all causes of nephrocalcinosis should be considered, including conditions associated with hypercalcemia, hypercalciuria without hypercalcemia, or hyperphosphatemia with hyperphosphaturia. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nephrocalcinosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important preventive strategy is to identify patients who are at higher risk for the development of acute phosphate nephropathy and then avoid the administration of bowel purgatives that contain oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    , if possible. Specific recommendations for the choice of bowel preparation are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no specific treatment for established acute phosphate nephropathy. However, acute hemodialysis is likely to be beneficial in the infrequent patient who is diagnosed within 12 to 24 hours after OSP administration and still has marked hyperphosphatemia. As noted above, most patients are diagnosed later and, since complete recovery of renal function is rare, these patients should be treated the same as others with chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Acute phosphate nephropathy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute phosphate nephropathy is a clinicopathologic entity which results from colonic cleansing with bowel purgatives that contain oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      (OSP). Acute phosphate nephropathy has also been reported following the administration of sodium phosphate-containing enemas. Acute phosphate nephropathy is usually detected days to months following OSP administration. This entity is complicated by the development of chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of acute phosphate nephropathy is related to volume depletion and transient OSP-induced hyperphosphatemia and involves precipitation of calcium phosphate crystals in the distal tubule. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal biopsy reveals an acute and chronic tubulointerstitial nephropathy with the distinctive finding of abundant tubular and interstitial deposits of calcium phosphate. In biopsies performed within three weeks of OSP exposure, findings of acute tubular injury predominate and resemble changes seen in acute tubular necrosis. Later biopsies exhibit findings of chronicity, including tubular atrophy and interstitial fibrosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of acute phosphate nephropathy remains unknown. Acute phosphate nephropathy can occur in patients with normal renal function. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apparent risk factors for acute phosphate nephropathy include advanced age, hypertension, renal dysfunction, volume depletion and the use of ACE inhibitors or ARBs. Possible additional risk factors include the use of diuretics, nonsteroidal antiinflammatory agents or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , the presence of diabetes, and female gender. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful review of all contraindications to the use of OSP should be done prior to selection of a bowel purgative for an individual patient. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific recommendations for the choice of bowel preparation are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"       \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/1\">",
"      Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney Int 2009; 76:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/2\">",
"      Ori Y, Rozen-Zvi B, Chagnac A, et al. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med 2012; 172:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/3\">",
"      Vanner SJ, MacDonald PH, Paterson WG, et al. A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy. Am J Gastroenterol 1990; 85:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/4\">",
"      Cohen SM, Wexner SD, Binderow SR, et al. Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. Dis Colon Rectum 1994; 37:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/5\">",
"      Golub RW, Kerner BA, Wise WE Jr, et al. Colonoscopic bowel preparations--which one? A blinded, prospective, randomized trial. Dis Colon Rectum 1995; 38:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/6\">",
"      Tan JJ, Tjandra JJ. Which is the optimal bowel preparation for colonoscopy - a meta-analysis. Colorectal Dis 2006; 8:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/7\">",
"      Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003; 349:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/8\">",
"      Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/9\">",
"      Markowitz GS, Whelan J, D'Agati VD. Renal failure following bowel cleansing with a sodium phosphate purgative. Nephrol Dial Transplant 2005; 20:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/10\">",
"      Demoulin N, Jadoul M, Cosyns JP, Labriola L. An easily overlooked iatrogenic cause of renal failure. Clin Nephrol 2008; 70:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/11\">",
"      Steinman TI, Samir AE, Cornell LD. Case records of the Massachusetts General Hospital. Case 27-2008. A 64-year-old man with abdominal pain, nausea, and an elevated level of serum creatinine. N Engl J Med 2008; 359:951.",
"     </a>",
"    </li>",
"    <li>",
"     Center of Drug Evaluation Research. U.S. Food and Drug Administration. Oral sodium phosphate (OSP) products for bowel cleansing. US government Printing Office: Washington, DC, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/13\">",
"      American Society of Colon and Rectal Surgeons (ASCRS), American Society for Gastrointestinal Endoscopy (ASGE), Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), et al. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Surg Endosc 2006; 20:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Center of Drug Evaluation Research. U.S. Food and Drug Administration. Oral sodium phosphate (OSP) products for bowel cleansing (marketed as Visicol and OsmoPrep, and oral sodium phosphate products available without a prescription. US government Printing Office: Washington, DC, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/15\">",
"      Lieberman DA, Ghormley J, Flora K. Effect of oral sodium phosphate colon preparation on serum electrolytes in patients with normal serum creatinine. Gastrointest Endosc 1996; 43:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/16\">",
"      Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol 2004; 19:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/17\">",
"      Murer H, Hernando N, Forster L, Biber J. Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption (plenary lecture). Mol Membr Biol 2001; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/18\">",
"      Forster IC, Hernando N, Biber J, Murer H. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int 2006; 70:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/19\">",
"      Heher EC, Thier SO, Rennke H, Humphreys BD. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. Clin J Am Soc Nephrol 2008; 3:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/20\">",
"      Mishra R, Kaufman D, Mattern J 3rd, Dutta SK. Severe hyperphosphatemia and hypocalcemia caused by bowel preparation for colonoscopy using oral sodium phosphate in end-stage renal disease. Endoscopy 2005; 37:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/21\">",
"      Wechsler A, Schneider R, Sapojnikov M, et al. Bowel cleansing in patients with chronic renal failure--an often overlooked hazard. Nephrol Dial Transplant 2006; 21:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/22\">",
"      Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet Phospo-Soda in a patient with colonic ileus. Am J Gastroenterol 1993; 88:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/23\">",
"      Hebert LA, Lemann J Jr, Petersen JR, Lennon EJ. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966; 45:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/24\">",
"      Markowitz GS, Nasr SH, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/25\">",
"      Asplin JR, Mandel NS, Coe FL. Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol 1996; 270:F604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/26\">",
"      Verhulst A, Asselman M, De Naeyer S, et al. Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int 2005; 68:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/27\">",
"      Khurana A, McLean L, Atkinson S, Foulks CJ. The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med 2008; 168:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/28\">",
"      Brunelli SM, Lewis JD, Gupta M, et al. Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol 2007; 18:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/29\">",
"      Tenenhouse HS, Gauthier C, Martel J, et al. Na+ -phosphate cotransport in mouse distal convoluted tubule cells: evidence for Glvr-1 and Ram-1 gene expression. J Bone Miner Res 1998; 13:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/30\">",
"      Hesse A, Heimbach D. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 1999; 17:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/31\">",
"      Hurst FP, Bohen EM, Osgard EM, et al. Association of oral sodium phosphate purgative use with acute kidney injury. J Am Soc Nephrol 2007; 18:3192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/32\">",
"      Russmann S, Lamerato L, Marfatia A, et al. Risk of impaired renal function after colonoscopy: a cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. Am J Gastroenterol 2007; 102:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/33\">",
"      Markowitz GS, Radhakrishnan J, D'Agati VD. Towards the incidence of acute phosphate nephropathy. J Am Soc Nephrol 2007; 18:3020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/34\">",
"      Barclay RL. Safety, efficacy, and patient tolerance of a three-dose regimen of orally administered aqueous sodium phosphate for colonic cleansing before colonoscopy. Gastrointest Endosc 2004; 60:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/35\">",
"      Hookey LC, Depew WT, Vanner SJ. A prospective randomized trial comparing low-dose oral sodium phosphate plus stimulant laxatives with large volume polyethylene glycol solution for colon cleansing. Am J Gastroenterol 2004; 99:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/36\">",
"      Rostom A, Jolicoeur E, Dub&eacute; C, et al. A randomized prospective trial comparing different regimens of oral sodium phosphate and polyethylene glycol-based lavage solution in the preparation of patients for colonoscopy. Gastrointest Endosc 2006; 64:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/37\">",
"      Russmann S, Lamerato L, Motsko SP, et al. Risk of further decline in renal function after the use of oral sodium phosphate or polyethylene glycol in patients with a preexisting glomerular filtration rate below 60 ml/min. Am J Gastroenterol 2008; 103:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/38\">",
"      Ainley EJ, Winwood PJ, Begley JP. Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. Dig Dis Sci 2005; 50:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/39\">",
"      Martin RR, Lisehora GR, Braxton M Jr, Barcia PJ. Fatal poisoning from sodium phosphate enema. Case report and experimental study. JAMA 1987; 257:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/40\">",
"      Korzets A, Dicker D, Chaimoff C, Zevin D. Life-threatening hyperphosphatemia and hypocalcemic tetany following the use of fleet enemas. J Am Geriatr Soc 1992; 40:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/41\">",
"      Gonlusen G, Akgun H, Ertan A, et al. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med 2006; 130:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/42\">",
"      Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/43\">",
"      Orias M, Mahnensmith RL, Perazella MA. Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am J Nephrol 1999; 19:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/44\">",
"      Manley P, Somerfield J, Simpson I, et al. Bilateral uraemic optic neuritis complicating acute nephrocalcinosis. Nephrol Dial Transplant 2006; 21:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/45\">",
"      Aaseb&oslash; W, Scott H, Ganss R. Kidney biopsies taken before and after oral sodium phosphate bowel cleansing. Nephrol Dial Transplant 2007; 22:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7032/abstract/46\">",
"      Beyea A, Block C, Schned A. Acute phosphate nephropathy following oral sodium phosphate solution to cleanse the bowel for colonoscopy. Am J Kidney Dis 2007; 50:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7218 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7032=[""].join("\n");
var outline_f6_55_7032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Volume depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174443914\">",
"      Risk with sodium phosphate-containing enemas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute and reversible kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7218|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/39/9848\" title=\"picture 1\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_55_7033="Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient";
var content_f6_55_7033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7033/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7033/contributors\">",
"     Kenneth E Sherman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7033/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7033/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/55/7033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The worldwide epidemics of hepatitis B and HIV have led to new understanding of the complicated interactions between these two viruses. Coinfection with HIV has a major impact on the natural history, diagnosis, progression, and morbidity and mortality related to hepatitis B virus (HBV) infection. The presence of chronic hepatitis B can also lead to an increased risk of hepatotoxicity related to the administration of potent antiretroviral therapy (ART).",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient will be reviewed here. Treatment and prevention as well as issues related to hepatitis C and HIV coinfection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=see_link\">",
"     \"Prevention of hepatitis B virus infection in the HIV-infected adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV and HIV are often diagnosed in the same patient because they share similar routes of transmission. Chronic HBV affects approximately 10 percent of HIV-infected patients worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/1\">",
"     1",
"    </a>",
"    ] and a study of 16,248 HIV-infected patients in the United States found the prevalence of chronic HBV was 8 percent among unvaccinated participants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the rates of",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfection vary according to geographic region and are highest in sub-Saharan Africa and Asia, where most transmission occurs perinatally. In developed countries, laboratory markers of prior HBV infection are more common in men who have sex with men (MSM) and injection drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF CHRONIC HBV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients should have routine testing for HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The diagnosis of chronic hepatitis B in HIV-infected patients is the same as in HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/7\">",
"     7",
"    </a>",
"    ]. Interpretation of serologic markers of HBV is discussed separately, but issues related specifically to the diagnosis of HBV infection in the HIV-infected patient will be summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link&amp;anchor=H2#H2\">",
"     \"Serologic diagnosis of hepatitis B virus infection\", section on 'Serologic markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatitis B surface antigen (HBsAg) is the serologic hallmark of HBV infection and appears in serum one to ten weeks after acute exposure to HBV (",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60627 \" href=\"UTD.htm?40/60/41932\">",
"     table 1",
"    </a>",
"    ). This is followed by detection of IgM and then IgG anti-HBc. Most adult patients clear HBsAg and develop anti-HBs consistent with resolved infection. Persistence of HBsAg for more than six months implies chronic infection, which is associated with the presence of viremia as measured by HBV DNA. Patients with the presence of HBsAg require further laboratory evaluation as described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatitis B e antigen (HBeAg) is a marker of HBV replication and infectivity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/8\">",
"     8",
"    </a>",
"    ]. The presence of HBeAg is usually associated with high levels of HBV DNA in serum and active liver disease. Seroconversion from HBeAg to anti-HBe is usually associated with declines in serum HBV DNA and remission of liver disease. However, some patients continue to have active liver disease and high levels of HBV DNA in serum after loss of HBeAg (HBeAg-negative chronic hepatitis). The latter patients may have HBV variants that abolish or decrease the production of detectable HBeAg in serum. Thus, it is important for all patients who are HBsAg positive to have testing of HBV DNA regardless of HBeAg status.",
"   </p>",
"   <p>",
"    Patients with chronic hepatitis B are also categorized according to the level of their aminotransferases: normal, &lt;2 times, or &gt;2 times the upper limit of normal. Higher levels of aminotransferases tend to be associated with more active liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/8\">",
"     8",
"    </a>",
"    ]. Aminotransferases also are important prognostic indicators when considering treatment. As an example, patients with serum ALT less than two times normal are less likely to have a treatment response to drugs such as interferon alfa and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Hepatitis D virus (HDV) is a defective virus that requires HBV to coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/9\">",
"     9",
"    </a>",
"    ]. HIV-infected patients with chronic hepatitis B infection should have an assay for anti-HDV at the initial visit or in the context of severe hepatic flares [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/10\">",
"     10",
"    </a>",
"    ]. In chronic HDV infection, markers of HBV replication are usually absent, and the patient is typically HBeAg negative and anti-HBe-positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link\">",
"     \"Diagnosis of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Isolated anti-HB core antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;Past exposure to hepatitis B is suggested by the presence of hepatitis B core (anti-HBc) and hepatitis B surface antibodies (anti-HBs). However, less than 2 percent of blood donors have anti-HBc in the absence of HBsAg and anti-HBs.",
"   </p>",
"   <p>",
"    Isolated detection of anti-HBc can occur in three settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the window period of acute hepatitis B when the anti-HBc is predominantly IgM class",
"     </li>",
"     <li>",
"      Many years after recovery from acute hepatitis B when anti-HBs has fallen to undetectable levels",
"     </li>",
"     <li>",
"      In the setting of low level HBV replication with production of small amounts of HBsAg that is cleared by anti-HBs. Immune escape mutants can rarely hamper detection of HBsAg [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of this serologic pattern is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link&amp;anchor=H5#H5\">",
"     \"Serologic diagnosis of hepatitis B virus infection\", section on 'Isolated anti-HBc'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated anti-HBc is more common in patients with underlying HIV infection than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/12-14\">",
"     12-14",
"    </a>",
"    ], particularly in patients who are also coinfected with hepatitis C virus (HCV) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In a study of 651 HIV-infected patients who were screened for the presence of anti-HBs and HBsAg, the following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 387 subjects who tested negative for both HBsAg and anti-HBs, 142 patients underwent further serologic testing. Sixty (42 percent) had evidence of isolated anti-HBc.",
"     </li>",
"     <li>",
"      Among these 60 patients, those coinfected with HCV were much more likely to have isolated anti-HBc than those without HCV (80 versus 16 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evolution of HBV serologic markers over time has also been evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During a five-year period serologic markers for hepatitis B were evaluated in a study of 633 HIV-infected patients in Taiwan, where the prevalence of HCV coinfection is low [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/17\">",
"       17",
"      </a>",
"      ]. During follow-up, changes in HBV serological markers were demonstrated in one-quarter of the patients. Among the 179 patients with isolated anti-HBc at baseline, 45 percent had persistence of this profile, 41 percent acquired anti-HBs, 10 percent lost anti-HBc, and 4 percent developed HBsAg. Those patients who gained anti-HBs had a significantly greater CD4 T-cell gain in response to ART than those who had persistence of an isolated anti-HBc pattern (223 versus 83",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      after 24 months of ART).",
"     </li>",
"     <li>",
"      A subsequent study in 282 HIV-infected patients and 40 HIV-seronegative patients over a median of 7.5 years found that 71 percent retained an isolated anti-HBc status, 20 percent acquired antibody to hepatitis B surface antigen, and 2 percent acquired hepatitis B surface antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/18\">",
"       18",
"      </a>",
"      ]. In a multivariate analysis, use of potent ART was a significant predictor of anti-HBs acquisition, whereas women with hepatitis C viremia were more likely to retain their isolated anti-HBc status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that reevaluation of HBV markers after immune reconstitution with ART may be helpful in determining whether a patient is a potential candidate for immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Occult HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult HBV infection is defined by the presence of HBV DNA in the serum or liver of individuals with negative test results for HBsAg. The clinical impact of occult HBV is unclear, but flares of aminotransferases, advanced fibrosis, and hepatocellular carcinoma have been associated. The mechanisms leading to occult infection are unknown, but may include escape of immune recognition of changes in the S protein, methylation or disruption of key regulatory regions in the HBV genome, or modification of post-translational mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with isolated anti-HBc, there are conflicting data on the prevalence of occult HBV viremia. Some studies have found a less than 2 percent prevalence of HBV viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. In contrast, in a report in which HBV DNA was sampled repeatedly over time, viremia was detected in 51 of 57 patients in at least one specimen over a mean of 31 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/21\">",
"     21",
"    </a>",
"    ]. These disparate findings may be explained in part by transient viremia that is best captured with serial examinations and by variable sensitivity of the HBV DNA assays used in the reported studies. Occult HBV has also been uncommonly described in HIV-infected patients without any serologic markers of HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether individuals who test positive for isolated anti-HBc should be vaccinated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    is not certain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of hepatitis due to HBV is mainly immune-mediated and not due to cytopathic effects of the virus. Patients who spontaneously recover from HBV infection mount vigorous CD4+ and CD8+ T-cell responses to various HBV epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. By contrast, patients who develop chronic hepatitis B infection have narrowly focused T-cell responses.",
"   </p>",
"   <p>",
"    Although recovery from acute hepatitis B is associated with lifelong protective immunity, trace amounts of virus can be detected with sensitive techniques such as polymerase chain reaction. This suggests that residual virus is controlled by cellular and humoral immune responses and that viremia can reemerge in the setting of immunosuppression. As an example, patients receiving chemotherapy, corticosteroids, or HIV-infected patients with advanced immunosuppression can experience reactivation of HBV replication and hepatitis flares [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous serum aminotransferase flares during chronic HBV infection have been attributed to changes in the balance between immunologic responses to HBV and quantitative variations in viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/27\">",
"     27",
"    </a>",
"    ]. As mentioned above, hepatitis is due to immune-mediated mechanisms not direct viral injury. HBV-specific T cell responses have been detected in peripheral blood preceding HBeAg seroconversion that accompanies the flare.",
"   </p>",
"   <p>",
"    The factors that spontaneously increase T cell responses are not well understood. T cell responses can increase in response to a reduction in HBV viral load induced by HBV antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Virologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations of increased HBV replication and lower rates of HBeAg seroconversion in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients, compared to patients with HBV alone, suggest that virologic factors may also contribute to pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel -1G deletion in the HBV precore and core genes of six",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients and three HBV monoinfected patients was identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/29\">",
"     29",
"    </a>",
"    ]. This mutation introduced a frameshift that terminated the coding sequence of the HBV core and precore genes; however, HBeAg was still detected due to the continued presence of wild-type virus as a minority quasispecies. The following observations suggest that the -1G deletion may alter disease pathogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients had high HBV DNA levels that may be related to changes in virulence and replication capacity.",
"     </li>",
"     <li>",
"      The protein is truncated at the site of a major CD4 T-cell epitope of the HBV nucleocapsid antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HIV AND NATURAL HISTORY OF HBV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-related immunosuppression affects the natural history of HBV infection. Epidemiologic studies suggest the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/4,31-38\">",
"     4,31-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBV DNA levels and reactivation rates are higher in HIV-infected patients than in subjects with HBV alone; the risk of reactivation may be associated with low CD4 cell counts.",
"     </li>",
"     <li>",
"      Reappearance of HBsAg and HBV viremia has been documented in",
"      <span class=\"nowrap\">",
"       HIV/HBV",
"      </span>",
"      coinfected patients who had serologic markers consistent with resolved HBV infection.",
"     </li>",
"     <li>",
"      HIV-infected patients have lower rates of spontaneous clearance of HBeAg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predisposition for HIV-infected patients to develop chronic infection after exposure to HBV infection was well-illustrated in a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    study of HIV-seronegative and seropositive patients who were not previously infected with HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/39\">",
"     39",
"    </a>",
"    ]. Chronic HBV infection developed in 21 percent of HIV-infected patients compared to 7 percent of controls with HBV alone. This difference could not be explained entirely by more frequent acute HBV infection in the HIV-infected patients.",
"   </p>",
"   <p>",
"    The risk of reactivation in the setting of HIV disease was assessed in a retrospective study of 141 HBV-infected patients, 69 of whom had HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/35\">",
"     35",
"    </a>",
"    ]. HBeAg seroconversion rates were not affected by the presence of HIV infection. However, among 47 patients who did experience HBeAg seroconversion, reactivation (loss of anti-HBe with reappearance of HBeAg) occurred in eight subjects within two years of follow-up and was significantly associated with HIV infection (5 of 14 HIV-seropositive patients compared with 3 of 33 HIV-seronegative patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HIV AND LIVER DISEASE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies from the United States and Europe suggest that",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients may have faster rates of fibrosis progression and an increased risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC) than patients with HBV infection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/31,35,40-42\">",
"     31,35,40-42",
"    </a>",
"    ]. HCC also occurs at an earlier age among patients who are HIV-infected compared with HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In HIV-seronegative patients with chronic HBV infection, the level of HBV DNA has been associated with an increased risk of cirrhosis and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. These data may also have direct implications for",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients who tend to have higher levels of HBV DNA than patients with HBV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also many rationales to treat HIV in the",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patient. Both innate and adaptive immunity are important for the control of HBV infection; immunosuppression, secondary to uncontrolled HIV infection, is associated with liver-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/40\">",
"     40",
"    </a>",
"    ], whereas ART leads to immunologic recovery.",
"   </p>",
"   <p>",
"    There are conflicting data as to whether or not HIV affects the necroinflammatory changes on histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/36,48\">",
"     36,48",
"    </a>",
"    ]. Some studies have demonstrated less necroinflammatory changes in patients with concomitant HIV infection, while others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/34,49,50\">",
"     34,49,50",
"    </a>",
"    ]. These different findings may be related in part to differences in CD4 counts. Strong epidemiologic data suggest that end-stage liver disease is an important cause of death among patients with coinfection. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Effect of HIV on liver-related mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hepatitis D infection (HDV) may also contribute to faster progression rates in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patients. In a case control study of 104 patients in Taiwan with",
"    <span class=\"nowrap\">",
"     HIV/HBV,",
"    </span>",
"    26 of whom also had HDV infection, patients with triple infection had higher rates of hepatitis flares, cirrhosis, hepatic decompensation and death over the eight year period of observation",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/51\">",
"      51",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFECT OF HIV ON LIVER-RELATED MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HBV",
"    coinfected patients may have an increased risk of liver-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/31,35,40,41\">",
"     31,35,40,41",
"    </a>",
"    ]. The magnitude of this effect was evaluated in a cohort of 5293 men who have sex with men in which the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver-related mortality rates were higher in men with HIV and HBsAg compared with those with only HBsAg",
"      <span class=\"nowrap\">",
"       (14.2/1000",
"      </span>",
"      compared with",
"      <span class=\"nowrap\">",
"       0.8/1000).",
"      </span>",
"     </li>",
"     <li>",
"      In coinfected individuals, the liver-related mortality rate was highest among those with lower nadir CD4 T-cell counts, a finding that has been seen in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The liver-related mortality rates doubled after the introduction of ART (12.3 to 24.7 per 1000 person years). This effect may be related to decreased AIDS-related mortality on ART, which may have unmasked underlying liver-related disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFECT OF HBV ON HIV PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There remains controversy about whether chronic hepatitis B affects the natural history of HIV.",
"   </p>",
"   <p>",
"    On one hand, some observations raised concern that HBV infection was associated with a more accelerated course of HIV progression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. One study of 1302 HIV-infected patients and 262",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients in Nigeria found that high levels of HBV replication were associated with lower CD4 cell counts at ART initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/55\">",
"     55",
"    </a>",
"    ]. Another observational study examined 2352 HIV seroconverters including 474 (20 percent) with resolved HBV, 82 (3 percent) with isolated core antibody, and 64 (3 percent) with chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/56\">",
"     56",
"    </a>",
"    ]. This retrospective analysis demonstrated that the risk of AIDS or death was almost twofold higher among those with chronic hepatitis B compared with HIV-monoinfected patients.",
"   </p>",
"   <p>",
"    However, two longitudinal studies and one retrospective study did not show any impact of HBV coinfection on CD4 depletion, progression to AIDS or AIDS related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Another retrospective study from the Multicenter AIDS Cohort found that HBV status did not influence viral suppression or immunologic recovery among those with chronic HBV infection who initiated ART [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EFFECT OF HBV ON ALL CAUSE MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis performed on data from 12,382 HIV-infected patients enrolled in 11 studies revealed a significant effect of",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfection on overall mortality (pooled effect estimate, 1.36; 95% CI 1.12-1.64) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HBV AND IMMUNE RECONSTITUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms \"immune reconstitution\" or \"immune reconstitution inflammatory syndrome\" (IRIS) describe a collection of inflammatory disorders associated with paradoxical worsening of preexisting infectious processes following the initiation of potent antiretroviral therapy (ART) in HIV-infected individuals. In HIV-infected patients with HBV, the immune reconstitution syndrome can have a negative or positive impact on an individual's clinical status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since HBV is an immunologically mediated disease, immune reconstitution with ART can alter the balance between host-viral interactions and modify the natural history of hepatitis B. In a prospective study of 36 treatment-naive patients initiating ART, baseline HBV DNA and ALT levels were significantly higher in the eight patients who developed hepatic flare (defined as ALT &gt;5x ULN or &gt;200 from baseline) than in those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/61\">",
"     61",
"    </a>",
"    ]. In a retrospective study of 394 patients initiating ART, 10 of 28 subjects who were coinfected with hepatitis B lost HBeAg in association with a transient hepatitis flare [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/62\">",
"     62",
"    </a>",
"    ]. Immune reconstitution in this scenario is associated with marked clinical benefit since loss of HBeAg is usually associated with declining viremia.",
"   </p>",
"   <p>",
"    CD8+ T-cell responses to HBV antigens that might produce such a change were evaluated in a study of HIV seropositive and HIV-seronegative patients who had markers of resolved HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/63\">",
"     63",
"    </a>",
"    ]. HIV infection was associated with a reduction in HBV-specific T-cell responses. The initiation of ART led to restoration of some functionally active T-cell responses. Furthermore, in patients who receive ART containing an agent with activity against HBV, T-cell responsiveness has been associated with reductions in HBV viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The improvement in HBV-specific T cell responses may involve two distinct processes: the reconstitution of responses associated with a reduction in HBV viremia; and the slow restoration of the immune system that occurs with suppression of HIV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/63\">",
"     63",
"    </a>",
"    ]. These in vitro observations may be the underpinning for clinical cases of HBV-related flares of aminotransferases and reactivation syndromes seen after the initiation of ART.",
"   </p>",
"   <p>",
"    HBV seroconversion has occurred after profound improvement in immune responses secondary to ART, even in the absence of effective HBV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune reconstitution in the HIV-infected patient with chronic hepatitis B can also lead to liver-related morbidity and mortality. Hepatitis flares secondary to immunologic recovery of HBV-specific T cells can be life threatening in the patient with little hepatic reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HBV AND RISK OF DRUG INDUCED HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both chronic hepatitis C and hepatitis B have been associated with an increased risk of drug induced liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The mechanism for the association between chronic viral hepatitis and risk of hepatotoxicity in HIV-infected patients is unknown.",
"   </p>",
"   <p>",
"    Drug-induced liver injury in association with chronic viral hepatitis may be related to advanced liver disease and its known association with decreased cytochrome P450 activity, which may lead to increased exposure to protease inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/69\">",
"     69",
"    </a>",
"    ]. Even modest declines of cytochrome P450 activity may be important in the face of potent inhibitors, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . However, some episodes of elevated aminotransferases may be related to underlying HBV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune reconstitution syndrome may explain flares of aminotransferases in the setting of ART-associated immunologic recovery of CD4 and CD8 T-cell function against HBV antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Withdrawal of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      therapy for HIV infection in patients with concomitant HBV liver disease has led to flares of aminotransferases due to viral rebound [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7033/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breakthrough infection due to HBV resistance while on anti-HBV therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HBeAg to anti-HBe seroconversion represents a change from a high to a low replicative stage and may be associated with ALT flares, which can be mistaken for drug-induced liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695868\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis B virus (HBV) infection and HIV are often diagnosed in the same patient because they share similar routes of transmission. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients should have routine testing for HBV infection. The diagnosis of chronic hepatitis B in HIV-infected patients is the same as in HIV-seronegative patients. Persistence of HBsAg for more than six months implies chronic infection, which is associated with the presence of viremia, as measured by HBV DNA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis of chronic HBV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of hepatitis due to HBV is mainly immune-mediated and not due to cytopathic effects of the virus. Observations of increased HBV replication and lower rates of HBeAg seroconversion in",
"      <span class=\"nowrap\">",
"       HIV/HBV",
"      </span>",
"      coinfected patients, compared with patients with HBV alone, suggest that virologic factors may also contribute to pathogenesis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV/HBV",
"      </span>",
"      coinfected patients have lower rates of spontaneous clearance and higher rates of reactivation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'HIV and natural history of HBV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV/HBV",
"      </span>",
"      coinfected patients may have an increased risk of liver-related mortality compared with patients with HBV infection alone. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effect of HIV on liver-related mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There remains controversy about whether chronic hepatitis B affects the natural history of HIV infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effect of HBV on HIV progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since HBV is an immunologically-mediated disease, immune reconstitution with antiretroviral therapy can alter the balance between host-viral interactions and modify the natural history of hepatitis B virus infection. In some patients, immune recovery can lead to spontaneous clearance, while in others with advanced liver disease, immune reconstitution can lead to liver failure. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'HBV and immune reconstitution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both chronic hepatitis C and hepatitis B have been associated with an increased risk of ART-associated hepatotoxicity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'HBV and risk of drug induced hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/1\">",
"      Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002; 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/2\">",
"      Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/3\">",
"      Rodr&iacute;guez-M&eacute;ndez ML, Gonz&aacute;lez-Quintela A, Aguilera A, Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000; 95:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/4\">",
"      McGovern BH. The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther 2007; 12 Suppl 3:H3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/5\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/6\">",
"      Thio CL. Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients. Antivir Ther 2007; 12 Suppl 3:H25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/7\">",
"      Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356:1445.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf (Accessed on February 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/9\">",
"      Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010; 202:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/10\">",
"      Jain MK, Opio CK, Osuagwu CC, et al. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis 2007; 44:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/11\">",
"      Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, et al. Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J Infect Dis 2008; 198:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/12\">",
"      Neau D, Winnock M, Jouvencel AC, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005; 40:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/13\">",
"      Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/14\">",
"      Witt MD, Lewis RJ, Rieg G, et al. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis 2013; 56:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/15\">",
"      French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007; 195:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/16\">",
"      Gandhi RT, Wurcel A, McGovern B, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/17\">",
"      Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/18\">",
"      French AL, Lin MY, Evans CT, et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis 2009; 49:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/19\">",
"      Vivekanandan P, Kannangai R, Ray SC, et al. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 2008; 46:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/20\">",
"      Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 2010; 55:3328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/21\">",
"      Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/22\">",
"      Shire NJ, Rouster SD, Stanford SD, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/23\">",
"      Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/24\">",
"      Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/25\">",
"      Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/26\">",
"      Martel N, Cotte L, Trabaud MA, et al. Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape. J Infect Dis 2012; 205:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/27\">",
"      Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/28\">",
"      Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/29\">",
"      Revill PA, Littlejohn M, Ayres A, et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS 2007; 21:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/30\">",
"      Ferrari C, Bertoletti A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991; 88:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/31\">",
"      Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/32\">",
"      Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/33\">",
"      Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/34\">",
"      Mills CT, Lee E, Perrillo R. Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 1990; 99:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/35\">",
"      Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/36\">",
"      Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/37\">",
"      Vento S, Di Perri G, Garofano T, et al. Reactivation of hepatitis B in AIDS. Lancet 1989; 2:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/38\">",
"      Piroth L, S&egrave;ne D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS 2007; 21:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/39\">",
"      Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/40\">",
"      Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/41\">",
"      Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/42\">",
"      Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/43\">",
"      Br&auml;u N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/44\">",
"      Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/45\">",
"      Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/46\">",
"      Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/47\">",
"      Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/48\">",
"      Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/49\">",
"      Housset C, Pol S, Carnot F, et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992; 15:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/50\">",
"      McDonald JA, Harris S, Waters JA, Thomas HC. Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol 1987; 4:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/51\">",
"      Sheng WH, Hung CC, Kao JH, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/52\">",
"      Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992; 6:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/53\">",
"      Twu SJ, Detels R, Nelson K, et al. Relationship of hepatitis B virus infection to human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/54\">",
"      Thio CL, Smeaton L, Saulynas M, et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 2013; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/55\">",
"      Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/56\">",
"      Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/57\">",
"      Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992; 117:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/58\">",
"      Sinicco A, Raiteri R, Sciandra M, et al. The influence of cytomegalovirus on the natural history of HIV infection: evidence of rapid course of HIV infection in HIV-positive patients infected with cytomegalovirus. Scand J Infect Dis 1997; 29:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/59\">",
"      Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/60\">",
"      Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/61\">",
"      Crane M, Oliver B, Matthews G, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 2009; 199:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/62\">",
"      den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/63\">",
"      Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis 2005; 191:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/64\">",
"      Lascar RM, Gilson RJ, Lopes AR, et al. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. J Infect Dis 2003; 188:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/65\">",
"      Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/66\">",
"      Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/67\">",
"      Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/68\">",
"      Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/69\">",
"      Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38 Suppl 2:S90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7033/abstract/70\">",
"      Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3640 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7033=[""].join("\n");
var outline_f6_55_7033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4695868\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS OF CHRONIC HBV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Isolated anti-HB core antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Occult HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Virologic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HIV AND NATURAL HISTORY OF HBV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIV AND LIVER DISEASE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFECT OF HIV ON LIVER-RELATED MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFECT OF HBV ON HIV PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EFFECT OF HBV ON ALL CAUSE MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HBV AND IMMUNE RECONSTITUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HBV AND RISK OF DRUG INDUCED HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4695868\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3640\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3640|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42398\" title=\"figure 1\">",
"      Serology acute and chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3640|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/60/41932\" title=\"table 1\">",
"      Serologic markers HBV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=related_link\">",
"      Diagnosis of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=related_link\">",
"      Prevention of hepatitis B virus infection in the HIV-infected adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_55_7034="Initial treatment of chronic myeloid leukemia in chronic phase";
var content_f6_55_7034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of chronic myeloid leukemia in chronic phase",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/55/7034/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/55/7034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t(9;22)(q34;q11) resulting in the BCR-ABL fusion gene. This genetic abnormality results in the formation of a unique gene product (BCR-ABL), which is a constitutively active tyrosine kinase. It is this deregulated tyrosine kinase that is implicated in the development of CML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibitors of this tyrosine kinase, most notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , have been developed and used successfully to treat CML. Even with therapy, CML can progress from a relatively indolent disease (chronic stable phase) to a more aggressive disorder (accelerated phase), during which time disease control is more difficult to achieve. It can then culminate in an acute leukemia, termed \"blast crisis\", which is generally refractory to treatment.",
"   </p>",
"   <p>",
"    The initial treatment of chronic phase CML will be discussed here. Treatment of chronic phase CML after the failure of initial therapy, treatment of accelerated phase and blast crisis, and specific details regarding the pharmacology of tyrosine kinase inhibitors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895608\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895616\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main treatment options for patients with newly diagnosed CML in chronic phase are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCR-ABL tyrosine kinase inhibitors (TKIs), such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Allogeneic hematopoietic cell transplantation (HCT).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allogeneic HCT remains the only treatment option with proven ability to cure CML and had been the mainstay for younger patients in chronic phase before the development of TKIs. However, as TKIs have demonstrated long term disease control and good tolerability, few patients choose to pursue allogeneic HCT as initial therapy. Instead, they are treated with TKIs and careful follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/1\">",
"     1",
"    </a>",
"    ]. Allogeneic HCT remains a principal therapeutic option for patients who develop resistance or intolerance to TKIs. Outcomes with HCT and TKIs have not been directly compared in a well-designed trial. However, historic comparisons have noted that HCT is associated with increased short and long term morbidity and mortality, despite the possibility of cure. Thus, allogeneic HCT is rarely offered as initial therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    was the first tyrosine kinase inhibitor available for the treatment of patients with chronic phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/2\">",
"     2",
"    </a>",
"    ]. Initial reports from randomized trials have demonstrated that more potent, second generation TKIs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) produce faster and deeper responses than imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, the clinical significance of these endpoints is unclear, as patients on imatinib could &ldquo;catch up&rdquo; in subsequent years, and there is no difference in survival. These randomized studies also noted an increased rate of progression to accelerated phase or blast crisis in the imatinib-treated patients in the first year. However, progression was seen in only 3 to 4 percent of imatinib-treated patients and there is no information available on the fate of these patients or the possibility of salvage treatment with a second generation TKI.",
"   </p>",
"   <p>",
"    Further follow-up is needed to confirm whether the substantial short term improvements seen with second generation TKIs will result in longer term benefits, such as improved survival. A choice among agents should take into consideration the drug side effect profiles and the patient's comorbidities. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Second generation TKIs'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Management of side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    gained approval as the initial treatment of choice for chronic phase CML based on prospective clinical trials, some of which are presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/6-15\">",
"     6-15",
"    </a>",
"    ]. These trials demonstrated more frequent cytogenetic responses and more durable responses when compared with interferon alpha plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , which was the previous standard of care for those unable to receive hematopoietic cell transplantation (HCT). Comparative survival benefits have not been reported; this is principally because of the large number of patients who crossed over to imatinib from the other treatment arm. The benefit of imatinib therapy appears to be similar in older and younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The currently approved starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for patients with chronic phase CML is 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    This drug is continued indefinitely in patients who continue to respond to treatment as assessed with molecular studies such as quantitative PCR or FISH. Side effects are mild or moderate. The most common adverse effects are edema, nausea, muscle cramps, rash, and diarrhea, occurring in approximately 60, 55, 50, 30, and 30 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/10\">",
"     10",
"    </a>",
"    ]. Grades 3 or 4 neutropenia, leukopenia, thrombocytopenia, or anemia occur in approximately 35, 25, 20, and less than 10 percent, respectively. More information on side effects of tyrosine kinase inhibitors and their management is present elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     IRIS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IRIS trial (International Randomized study of Interferon and STI571) was a phase III randomized, open-label, multicenter, crossover trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by mouth) versus interferon (5 million",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for 10",
"    <span class=\"nowrap\">",
"     days/month)",
"    </span>",
"    in 1106 patients with newly diagnosed chronic phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/17\">",
"     17",
"    </a>",
"    ]. On an intention-to-treat analysis, imatinib was significantly better than interferon plus cytarabine for all early endpoints studied, with the following 18-month estimates:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete hematologic response &mdash; 97 versus 69 percent",
"     </li>",
"     <li>",
"      Major cytogenetic response &mdash; 87 versus 35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Complete cytogenetic response &mdash; 76 versus 14 percent",
"     </li>",
"     <li>",
"      Major molecular response (absence of BCR-ABL using polymerase chain reaction [PCR]) &mdash; 39 versus 2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Progression-free survival &mdash; 97 versus 92 percent",
"     </li>",
"     <li>",
"      Drug intolerance &mdash; &lt;1 versus 25 percent",
"     </li>",
"     <li>",
"      Improved preservation of quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Updated results from the IRIS trial with a median follow-up of 60 months have shown that the results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    treatment have been durable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      as initial therapy for chronic phase CML had overall and event-free survivals of 89 and 83 percent, respectively.",
"     </li>",
"     <li>",
"      The annual rate of progression to accelerated phase or blast crisis was 0.6 percent in the fifth year of therapy, which was lower than that seen during the first four years of treatment (1.5, 2.8, 1.6, and 0.9 percent, respectively).",
"     </li>",
"     <li>",
"      Patients who achieved a complete cytogenetic response by 12 months after initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      had better overall survival without progression to accelerated phase or blast crisis (97 versus 81 percent) compared with patients who did not achieve at least a major cytogenetic response by 12 months.",
"     </li>",
"     <li>",
"      No patient who had a complete cytogenetic response along with a reduction of at least 3 log in levels of BCR-ABL transcripts at 12 months had progressed to the accelerated or blast crisis at 60 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These overall results and conclusions have help up with eight years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/22\">",
"     22",
"    </a>",
"    ]. It has not been possible to show a survival advantage for treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in the IRIS study since approximately 90 percent of patients randomly assigned to receive",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"      cytarabine",
"     </a>",
"    </span>",
"    crossed over to treatment with imatinib after a median time of nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/23\">",
"     23",
"    </a>",
"    ]. However, two",
"    <span class=\"nowrap\">",
"     historical/retrospective",
"    </span>",
"    comparisons have shown significantly better three-year overall survival following treatment with imatinib than with interferon-containing regimens: 92 versus 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/23\">",
"     23",
"    </a>",
"    ] and 96 versus 81 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective single-arm study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in 204 consecutive adults with newly diagnosed CML in chronic phase has reported similar patient outcomes to the imatinib arm of the IRIS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/25\">",
"     25",
"    </a>",
"    ]. At a median follow-up of five years, rates of complete cytogenetic response and major molecular response were 83 and 50 percent, respectively. Five-year overall survival and progression free survival rates were each 83 percent. A quarter of patients discontinued imatinib due to resistance or intolerance. Sixty-three percent of patients continue to receive imatinib and remain in complete cytogenetic response at five years. This smaller trial confirms the results seen in IRIS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Higher dose imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently approved starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for patients with chronic phase CML is 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    There has been interest in using higher doses as initial treatment since data indicates superior responses using 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients with CML in accelerated or blast phase.",
"   </p>",
"   <p>",
"    Non-randomized, phase II trials have examined the initial use of higher dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/26-31\">",
"     26-31",
"    </a>",
"    ]. High-dose imatinib therapy was fairly well tolerated, although dose reductions to 400 or 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    were required in about one-third of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. Myelosuppression was more frequent than with \"standard dose\" imatinib, but could be managed through dose reductions or use of erythropoietin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Randomized trials have compared starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    doses of 400 mg and 600 to 800 mg in newly diagnosed patients with chronic phase CML:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 400 versus 800 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in CML patients with high Sokal scores demonstrated a nonsignificant increase in complete cytogenetic response (CCyR) at one year (64 versus 58 percent) for patients receiving the higher initial dose, but no differences in cytogenetic response rates at three or six months or in the molecular response rate at any time [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second randomized trial (TOPS) comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      doses of 400 and 800 mg in 476 newly diagnosed patients with chronic phase CML of all Sokal risk groups reported that patients assigned to receive the higher dose of imatinib achieved major molecular response (MMR) and CCyR more rapidly (ie, at 3 and 6 months), but that there was no significant difference in the percent of patients in each treatment arm who achieved a MMR or CCyR by 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/34\">",
"       34",
"      </a>",
"      ]. A post-hoc analysis of patients in the 800 mg arm who maintained a dose intensity of at least 600 mg found a greater probability of achieving MMR, while dose interruptions of more than five days were associated with inferior outcomes.",
"     </li>",
"     <li>",
"      The phase III STI571 Prospective Randomized Trial (SPIRIT) randomly assigned 636 patients to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (400 mg daily), imatinib plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , imatinib plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      , or imatinib 600 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/35\">",
"       35",
"      </a>",
"      ]. When compared with standard dose imatinib, imatinib 600 mg resulted in a significantly higher rate of CCyR at six months (69 versus 50 percent), but similar rates of CCyR at 12 months (65 versus 58 percent) and MMR at 18 months (50 versus 42 percent). Side effects were more common with imatinib 600 mg. Progression to accelerated phase or blast crisis was seen in four and five patients receiving imatinib 400 mg and 600 mg, respectively.",
"     </li>",
"     <li>",
"      The phase III CONSORT trial randomly assigned 1014 patients with newly diagnosed CML to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      400 mg daily, imatinib 400 mg daily plus interferon alpha, or imatinib 800 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients assigned to imatinib 800 mg daily had doses adjusted based on tolerance such that the median dose was 628 mg daily. Although patients assigned to imatinib 800 mg daily achieved a major molecular response more rapidly than those assigned to 400 mg daily, the difference in the rate of complete cytogenetic response by 18 months (75 versus 66 percent) was not statistically significant. Estimated rates of overall survival and progression-free survival at three years were 95 and 94 percent, respectively and did not differ among treatment groups. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is too early to come to any conclusions about progression-free survival or overall survival with higher dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ; further follow-up of a non-randomized comparison between 400 and 800 mg suggests that the longer term results may be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/27\">",
"     27",
"    </a>",
"    ]. For patients with newly diagnosed CML in chronic phase, we suggest initial treatment with imatinib 400 mg daily rather than 600 mg or 800 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Imatinib plus other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies have investigated adding other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , interferon) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for newly diagnosed patients with CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/35,37-39\">",
"     35,37-39",
"    </a>",
"    ]. In general, the addition of other agents to imatinib therapy results in quicker responses, but increased toxicity.",
"   </p>",
"   <p>",
"    As described above, the SPIRIT trial randomly assigned treatment of 636 patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (400 mg daily), imatinib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , imatinib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    (peginterferon), or imatinib 600 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/35\">",
"     35",
"    </a>",
"    ]. When compared with standard dose imatinib, imatinib plus peginterferon resulted in a significantly higher rate of major molecular response (MMR) at 12 months (57 versus 38 percent) and 24 months (64 versus 43 percent), but was associated with more side effects requiring discontinuation (eg, rash, depression, cytopenia). Although only 46 percent of patients assigned to this combination were able to tolerate treatment for 12 months, those who received both agents for at least 12 months had the highest rates of MMR (82 percent) and undetectable residual disease (20 percent). Longer follow-up is needed to determine whether the more rapid achievement of MMR will result in improved PFS or overall survival, particularly since the rates of CCyR were similar in the two treatment arms. In comparison, the combination of imatinib plus cytarabine resulted in more gastrointestinal toxicity and similar response rates to those seen with imatinib alone. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Higher dose imatinib'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another phase III trial of 130 patients with chronic phase CML who had achieved a complete hematologic remission with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy randomly assigned further therapy with imatinib alone or imatinib in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/40\">",
"     40",
"    </a>",
"    ]. When compared with imatinib alone, imatinib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    resulted in a significantly higher rate of MMR at 12 months (82 versus 54 percent) and the MMR rate increased with the duration of interferon treatment. However, toxicity with interferon was significant with 61 percent of patients discontinuing interferon due to side effects.",
"   </p>",
"   <p>",
"    A phase II trial combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (200 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by mouth) with two cycles of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (200 or 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 7) in 162 previously untreated patients with chronic phase CML with a median follow-up of 55 months reported cumulative incidences of complete cytogenetic response, MMR, and complete molecular response at five years of 89, 71, and 53 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/39\">",
"     39",
"    </a>",
"    ]. Progression-free and overall survival rates at five years were 92 and 96 percent, respectively.",
"   </p>",
"   <p>",
"    Since more potent tyrosine kinase inhibitors have been evaluated in large phase III trials, there is little interest in combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    with cytotoxic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Second generation TKIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , more potent, second generation tyrosine kinase inhibitors (TKIs) have been developed. The three second generation TKIs that have been studied the most extensively are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    . Dasatinib and nilotinib have been approved by the US Food and Drug Administration and are widely used for the treatment of patients intolerant of or who have a primary or secondary resistance to imatinib.",
"   </p>",
"   <p>",
"    Phase III trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    (DASISION) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    (ENESTnd) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    as initial therapy for CML in chronic phase have demonstrated faster and deeper responses with these second generation TKIs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These studies are described in more detail in the following sections. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Nilotinib'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Dasatinib'",
"    </a>",
"    below.) Further follow-up is needed to confirm whether the substantial short term improvements will result in longer term benefits, such as improved survival. However, based on these results, nilotinib and dasatinib have been granted accelerated approval for the treatment of newly diagnosed CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial comparing the investigational agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (BELA) in newly diagnosed patients, noted that bosutinib resulted in higher rates of discontinuation due to toxicity, slightly improved response rates, and less treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult at this time to recommend one TKI over another for individual patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    have not been compared directly, but further follow-up of the randomized trials might eventually provide further insights about the initial choice of second generation TKI. The side effect profiles of both dasatinib and nilotinib are different from each other and compare favorably to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . A choice among agents should take into consideration these drug side effect profiles and the patient's comorbidities.",
"   </p>",
"   <p>",
"    For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    might be preferred in a patient with a history of pancreatitis, elevated bilirubin, or hyperglycemia, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    might be chosen for a patient with a history of pleural or pericardial disease or effusions. Patient preference related to the different schedules (daily with food versus twice a day on an empty stomach) might also be a consideration for some individuals.",
"   </p>",
"   <p>",
"    Patients who are currently being treated successfully with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    who have achieved complete cytogenetic response with good tolerance of the side effects, should be continued on imatinib and should not be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nilotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    has been evaluated as first line treatment for patients with chronic phase CML in several phase II trials and in a randomized phase III trial comparing it to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Nilotinib has been granted accelerated approval by the US Food and Drug Administration for the treatment of newly diagnosed CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/41\">",
"     41",
"    </a>",
"    ]. The approved dose is 300 mg twice daily. Initial treatment with nilotinib results in faster and deeper responses than those seen with imatinib. Nilotinib has not been directly compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A 1:1:1 randomized trial (ENESTnd) compared two different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    (300 mg twice daily or 400 mg twice daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 846 previously untreated patients with CML in chronic phase, stratified by Sokal risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/4,46,47\">",
"     4,46,47",
"    </a>",
"    ]. With a minimum follow-up of three years, those patients assigned to nilotinib therapy had the following outcomes compared with imatinib:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of major molecular response (MMR) at 12 months (44 and 43 versus 22 percent, respectively), 24 months (71 and 67 versus 44 percent, respectively), and 36 months (73 versus 70 versus 53 percent, respectively)",
"     </li>",
"     <li>",
"      Higher cumulative rates of complete cytogenetic response at 24 months (87 and 85 versus 77 percent, respectively)",
"     </li>",
"     <li>",
"      Higher rates of complete molecular response at 24 months (26 and 21 versus 10 percent, respectively) and MR",
"      <sup>",
"       4",
"      </sup>",
"      at 36 months (50 versus 44 versus 26 percent, respectively)",
"     </li>",
"     <li>",
"      Higher rates of progression-free survival at 36 months (97 versus 98 versus 95 percent, respectively)",
"     </li>",
"     <li>",
"      Similar rates of overall survival at 24 months (97, 98, and 96 percent, respectively) and 36 months (95, 97, and 94 percent, respectively)",
"     </li>",
"     <li>",
"      Lower rates of drug discontinuation (19 and 26 versus 38 percent, respectively). Discontinuations due to adverse events were observed in 10 and 14 versus 11 percent. Discontinuations due to disease progression were observed in 10 and 5 versus 20 percent.",
"     </li>",
"     <li>",
"      Lower rates of nausea, vomiting, muscle spasms, diarrhea, and fluid retention",
"     </li>",
"     <li>",
"      Higher rates of rash, headache, pruritus, hyperglycemia, and alopecia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    may be associated with QT prolongation. The US Food and Drug Administration issued a Risk Evaluation and Mitigation Strategy (REMS) to minimize the occurrence of QT prolongation and its sequelae in patients receiving nilotinib [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/48\">",
"     48",
"    </a>",
"    ]. Abnormalities in potassium and magnesium levels must be corrected prior to drug initiation, other drugs that may affect the QT interval should be avoided, and caution should be used in patients at risk for QT interval prolongation. Electrocardiograms should be obtained at baseline, after one week of treatment, with any dose change, and serially during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/49\">",
"     49",
"    </a>",
"    ]. An analysis of both dose arms of the ENESTnd trial was reassuring with regard to this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/47\">",
"     47",
"    </a>",
"    ]. There was a very low incidence of cardiovascular events, no deaths, with a &lt;1.5 percent incidence of significant QTc prolongation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'QT prolongation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports have described the development of severe peripheral artery occlusive disease thought to be related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    in patients without other vascular risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Cardiovascular'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    produces faster, deeper responses with a different side effect profile. Dasatinib has not been directly compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    . Dasatinib has been granted accelerated approval by the US Food and Drug Administration for the treatment of newly diagnosed CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/42\">",
"     42",
"    </a>",
"    ]. The approved dosing schedule is 100 mg once daily.",
"   </p>",
"   <p>",
"    A randomized phase III trial (DASISION) in 518 patients with previously untreated CML in chronic phase compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    100 mg daily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    400 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/3,50,51\">",
"     3,50,51",
"    </a>",
"    ]. An initial report after a minimum of 12 months of follow-up demonstrated that patients assigned to dasatinib therapy had significantly higher rates of confirmed complete cytogenetic response (77 versus 66 percent) and major molecular response (46 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/3\">",
"     3",
"    </a>",
"    ]. A subsequent report demonstrated that the difference in complete cytogenetic response had lost statistical significance by 24 months (85 versus 82 percent), but that the improvement in rates of major molecular response (64 versus 46 percent) remained [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/50\">",
"     50",
"    </a>",
"    ]. As yet there is no significant difference in progression-free survival (94 versus 92 percent), failure-free survival (91 versus 88 percent), or overall survival (95 percent for both). Similar rates of progression-free (91 versus 90 percent) and overall (93 percent each) survival were seen at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/51\">",
"     51",
"    </a>",
"    ]. Drug discontinuation was observed in 23 and 25 percent of those assigned to therapy with dasatinib and imatinib, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/50\">",
"     50",
"    </a>",
"    ]. Dasatinib was associated with fewer patients discontinuing due to progression or treatment failure (22 versus 28 patients), but more patients discontinuing treatment due to drug-related adverse events (18 versus 12 patients). Dasatinib therapy was associated with lower rates of nausea, vomiting, rash, and myalgia, but higher rates of thrombocytopenia and pleural effusions.",
"   </p>",
"   <p>",
"    Similar results were noted in a randomized phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    (100 mg daily) versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (400 mg daily) in 246 patients with newly diagnosed CML in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/52\">",
"     52",
"    </a>",
"    ]. Dasatinib resulted in higher rates of complete cytogenetic response (84 versus 69 percent) and major molecular response at 12 months (59 versus 44 percent), but after a median follow-up of three years, estimated rates of overall survival (97 percent each), progression-free survival (93 versus 90 percent), and relapse-free survival (91 versus 88 percent) at three years were similar. Toxicities differed between agents with edema, nausea and muscle pain being common with imatinib and pleural effusions, headache, and diarrhea being more common with dasatinib.",
"   </p>",
"   <p>",
"    A randomized phase II trial examined the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    50 mg twice daily or 100 mg daily in 50 patients with previously untreated chronic phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/53\">",
"     53",
"    </a>",
"    ]. At a median follow-up of 24 months, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients achieved a complete hematologic response at a median time of four weeks (range: 0.3 to 24 weeks).",
"     </li>",
"     <li>",
"      The overall rates of complete cytogenetic response at 12 months were 100 and 95 percent for the once daily and twice daily arms, respectively. The corresponding rates of major molecular response were 71 percent in both arms.",
"     </li>",
"     <li>",
"      There was no significant difference in grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      toxicities by treatment schedule. Thirty-five percent of patients required dose reductions, although the median dose for all patients at 12 months was 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (range: 20 to 100). Grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      toxicities included neutropenia (21 percent) and thrombocytopenia (10 percent). Pleural effusions occurred in eight patients (13 percent), 7 of these were grade 1 or 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15772961\">",
"    <span class=\"h3\">",
"     Bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    is a second generation BCR-ABL tyrosine kinase inhibitor approved by the US Food and Drug Administration for the treatment of CML in chronic phase after failure of initial therapy. When compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in newly diagnosed CML, bosutinib produces slightly improved response rates, but is associated with greater toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H1349640#H1349640\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Bosutinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized phase III trial (BELA) compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    (500 mg daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (400 mg daily) in 502 patients with newly diagnosed CML in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/43\">",
"     43",
"    </a>",
"    ]. After a minimum follow-up of 12 months, when compared with imatinib, bosutinib resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar rates of complete cytogenetic response (CCyR) (70 versus 68 percent) and major cytogenetic response (73 versus 78 percent) at 12 months.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"       Bosutinib",
"      </a>",
"      resulted in a shorter median time to first CCyR (13 versus 25 weeks).",
"     </li>",
"     <li>",
"      A higher rate of major molecular response at 12 months (41 versus 27 percent).",
"     </li>",
"     <li>",
"      A higher incidence of diarrhea (68 versus 21 percent), vomiting (32 versus 13 percent), and abdominal pain (11 versus 5 percent).",
"     </li>",
"     <li>",
"      A lower incidence of edema (11 versus 38 percent), bone pain (4 versus 10 percent), and muscle spasms (2 versus 20 percent).",
"     </li>",
"     <li>",
"      A higher rate of drug discontinuation due to adverse events (19 versus 6 percent). Adverse events leading to drug discontinuation in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"       bosutinib",
"      </a>",
"      included elevated aminotransferase, vomiting, anaphylactic shock, dissociative disorder, dyspepsia, elevated lipase, thrombocytopenia, and rash.",
"     </li>",
"     <li>",
"      In most patients, the diarrhea can be managed symptomatically and decreases substantially after one to two months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    appears to result in faster and slightly deeper responses than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , although its use in the treatment of newly diagnosed CML may be affected by short term side effects. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities with bosutinib were elevated ALT (22 percent), thrombocytopenia (14 percent), elevated AST (11 percent), neutropenia (11 percent), diarrhea (11 percent), elevated lipase (9 percent), and vomiting (3 percent). Longer term follow-up is awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment option that comes at the cost of increased potential toxicity. Outcomes with HCT and tyrosine kinase inhibitors have not been directly compared in a well-designed trial. However, based upon historical comparisons, HCT is associated with increased morbidity and mortality, despite the possibility of cure. Thus, allogeneic HCT is currently not offered as initial therapy, except in rare circumstances.",
"   </p>",
"   <p>",
"    With HCT, the probability of survival can be predicted with reasonable accuracy using a scoring system devised by the European Group for Blood and Marrow Transplantation (EBMT) (",
"    <a class=\"graphic graphic_table graphicRef67260 \" href=\"UTD.htm?35/31/36348\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/54\">",
"     54",
"    </a>",
"    ]. The five-year overall survival rates for patients in the best risk groups ranged from 60 to 80 percent. However, with the advent of newer approaches to HCT, current overall survival rates are likely to be higher. As an example, a prospective trial of HCT in patients in first chronic phase, most of who had failed to respond to initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , reported a transplant-related mortality rate of 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/55\">",
"     55",
"    </a>",
"    ]. Graft-versus-host disease (GVHD) was seen in 54 percent of patients with 36 percent demonstrating chronic GVHD. The overall survival rate at three years was 88 percent, demonstrating the safety of transplantation after imatinib treatment.",
"   </p>",
"   <p>",
"    Among patients with newly diagnosed CML in chronic phase, we recommend initial treatment with a BCR-ABL tyrosine kinase inhibitor rather than HCT. HCT may be considered in rare circumstances, such as that of a younger patient with an HLA matched sibling donor (EBMT score of 0) (",
"    <a class=\"graphic graphic_table graphicRef67260 \" href=\"UTD.htm?35/31/36348\">",
"     table 1",
"    </a>",
"    ). In this setting, HCT may be preferred since it offers the possibility of cure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MONITORING DISEASE STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overwhelming majority of patients with chronic phase CML will respond to treatment with tyrosine kinase inhibitors (TKIs). Even so, it is important to monitor the patient's disease status at regular intervals in order to detect patients who do not respond optimally and those who fail therapy after an initial response. This allows for the initiation of second line therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of monitoring schedules for patients with CML are acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/56\">",
"     56",
"    </a>",
"    ]. One approach to monitoring disease in patients in chronic phase would be the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After diagnosis, weekly complete blood counts with differential should be monitored until stable.",
"     </li>",
"     <li>",
"      If the patient achieves a complete hematologic response at any point and the counts are stable, the following should be performed every three months: complete blood counts, chemistries, and quantitative RT-PCR or FISH on the peripheral blood. Bone marrow cytogenetics should be performed when the peripheral blood FISH is zero to 5 percent positive or the RT-PCR is at a value corresponding to a complete cytogenetic response.",
"     </li>",
"     <li>",
"      If the patient achieves a complete cytogenetic response, the following is performed every three to four months: complete blood count with differential and quantitative RT-PCR or FISH on the peripheral blood. Bone marrow cytogenetics should be repeated when there are significant rises in the peripheral blood quantitative PCR. Some centers advocate bone marrow cytogenetics every 18 to 24 months in patients in complete cytogenetic response to evaluate for the presence of clonal abnormalities in Philadelphia chromosome negative cells. Since there is no consensus on the clinical impact of such changes, this area remains controversial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definitions of hematologic, cytogenetic, and molecular responses are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     AIMS OF INITIAL THERAPY AND DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of initial therapy with a tyrosine kinase inhibitor (TKI) is to achieve the following milestones (",
"    <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete hematologic response by three to six months",
"     </li>",
"     <li>",
"      Any cytogenetic response by six months",
"     </li>",
"     <li>",
"      Major cytogenetic response by 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Complete cytogenetic response by 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Monitoring response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the TKI is not tolerated or these milestones have not been achieved or have been lost, therapy should be altered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If these milestones have been realized, therapy with the TKI is continued indefinitely at the same dose as tolerated. This is principally because, if a TKI is discontinued, a substantial proportion of patients relapse (over 50 percent during the next year) since tumor cells remain in a quiescent state despite therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/59-65\">",
"     59-65",
"    </a>",
"    ]. As previously mentioned, patients who continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    progress at an annual rate of 0.6 to 2.8 percent per year.",
"   </p>",
"   <p>",
"    This recommendation is supported by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In seven separate reports covering a total of 36 patients, 34 of whom were in complete molecular remission following the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , disease relapse occurred in 21 (58 percent) within 10 months of imatinib cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/66-71\">",
"       66-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report involving nine patients with CML in complete hematologic remission (CHR) who discontinued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      immediately on recognition of pregnancy, five (56 percent) eventually lost their CHR status and six experienced an increase in Ph+ metaphases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/72\">",
"       72",
"      </a>",
"      ]. At a median period of 18 months following resumption of treatment with imatinib after delivery or abortion, all nine women were in CHR, but only three were able to attain complete cytogenetic remission, and none achieved complete molecular response.",
"     </li>",
"     <li>",
"      Results are also available from a study in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      was given to patients with early relapse following allogeneic transplantation for CML in chronic phase (ie, PCR-positive minimal residual disease or positive cytogenetics) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/73\">",
"       73",
"      </a>",
"      ]. Of the 10 evaluable patients who discontinued imatinib, 6 (60 percent) lost their previously-attained complete molecular response (CMR). A second CMR was achievable in all six either by reinstitution of imatinib or use of donor lymphocyte infusion.",
"     </li>",
"     <li>",
"      A prospective multicenter study evaluated the discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in 69 patients with CML who had been in a CMR for two years or longer [",
"      <a class=\"abstract\" href=\"UTD.htm?6/55/7034/abstract/74\">",
"       74",
"      </a>",
"      ]. Relapse was detected by molecular analysis in 61 percent of patients, almost all by six months. While all of the relapsed patients responded to the reintroduction of imatinib, only 62 percent entered CMR again.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these observations, patients frequently ask about the possibility of stopping TKIs. This is particularly an issue among women of childbearing age since TKIs are teratogenic. Issues regarding the safety of TKIs when taken during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/58/12194?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with newly diagnosed CML in chronic phase, we recommend initial treatment with a BCR-ABL tyrosine kinase inhibitor (TKI) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Allogeneic hematopoietic cell transplantation (HCT) may be a reasonable alternative in rare circumstances, such as that of a younger patient with an HLA matched sibling donor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Imatinib'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Among the available BCR-ABL TKIs, the second generation TKIs nilotinib and dasatinib have shown improved clinical benefit over imatinib during the early treatment period. It is difficult at this time to recommend one TKI over another for individual patients. A choice among TKIs should take into consideration the drug side effect profiles and the patient's comorbidities. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Second generation TKIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We monitor the patient's disease status at regular intervals (approximately every three months) to detect those who do not respond optimally (primary resistance)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who fail therapy after an initial response (secondary resistance). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring disease status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use the following milestones as goals for initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef52082 \" href=\"UTD.htm?3/56/3981\">",
"       table 2",
"      </a>",
"      ). If imatinib is not tolerated or these milestones have not been achieved or have been lost, therapy should be altered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"       \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients who have achieved and maintained these milestones with a tyrosine kinase inhibitor (TKI), we recommend that the TKI be continued indefinitely (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/1\">",
"      Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012; 120:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/2\">",
"      Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/3\">",
"      Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/4\">",
"      Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/5\">",
"      Gurion R, Gafter-Gvili A, Vidal L, et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 2013; 98:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/6\">",
"      Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/7\">",
"      Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/8\">",
"      Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002; 117:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/9\">",
"      Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/10\">",
"      Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/11\">",
"      Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/12\">",
"      Palandri F, Iacobucci I, Martinelli G, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008; 26:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/13\">",
"      Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/14\">",
"      Hess G, Meyer RG, Schuch B, et al. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up. Am J Hematol 2008; 83:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/15\">",
"      Kantarjian H, O'Brien S, Garcia-Manero G, et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 2012; 118:3116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/16\">",
"      Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117:5591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/17\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/18\">",
"      Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/19\">",
"      Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/20\">",
"      Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/21\">",
"      Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/22\">",
"      Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (abstract 1126). Blood 2009; 114:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/23\">",
"      Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/24\">",
"      Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/25\">",
"      de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/26\">",
"      Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003; 102:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/27\">",
"      Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/28\">",
"      Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008; 112:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/29\">",
"      Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009; 113:3428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/30\">",
"      Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009; 27:4754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/31\">",
"      Cortes J, Quint&aacute;s-Cardama A, Jones D, et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 2011; 117:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/32\">",
"      Petzer AL, Wolf D, Fong D, et al. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 \"ISTAHIT\" study. Haematologica 2010; 95:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/33\">",
"      Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009; 113:4497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/34\">",
"      Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/35\">",
"      Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/36\">",
"      Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-&alpha; in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/37\">",
"      Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003; 102:4298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/38\">",
"      Deenik W, van der Holt B, Verhoef GE, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 111:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/39\">",
"      Deenik W, Janssen JJ, van der Holt B, et al. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2010; 95:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/40\">",
"      Simonsson B, Gedde-Dahl T, Markev&auml;rn B, et al. Combination of pegylated IFN-&alpha;2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118:3228.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216181.htm. Accessed June 18, 2010.",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf (Accessed on October 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/43\">",
"      Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/44\">",
"      Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114:4933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/45\">",
"      Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/46\">",
"      Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/47\">",
"      Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26:2197.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM217737.pdf (Accessed on August 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/49\">",
"      Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14:5325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/50\">",
"      Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/51\">",
"      Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase : DASISION 3-year follow-up (abstract 6504). J Clin Oncol 2012; 30:417s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/52\">",
"      Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012; 120:3898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/53\">",
"      Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/54\">",
"      Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/55\">",
"      Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/56\">",
"      Deininger MW. Management of early stage disease. Hematology Am Soc Hematol Educ Program 2005; :174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/57\">",
"      Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008; 112:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/58\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009; 113:6315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/59\">",
"      Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/60\">",
"      Angstreich GR, Matsui W, Huff CA, et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 2005; 130:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/61\">",
"      Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006; 107:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/62\">",
"      Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107:4532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/63\">",
"      Graham SM, J&oslash;rgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/64\">",
"      Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/65\">",
"      Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/66\">",
"      Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28 Suppl 1:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/67\">",
"      Ghanima W, Kahrs J, Dahl TG 3rd, Tjonnfjord GE. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 2004; 72:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/68\">",
"      Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 2004; 76:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/69\">",
"      Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/70\">",
"      Ali R, Ozkalemka F, Oz&ccedil;elik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005; 29:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/71\">",
"      Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/72\">",
"      Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/73\">",
"      Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23:7583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/55/7034/abstract/74\">",
"      Mahon FX, R&eacute;a D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11:1029.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4508 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7034=[""].join("\n");
var outline_f6_55_7034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H895608\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H895616\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - IRIS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Higher dose imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Imatinib plus other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Second generation TKIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nilotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15772961\">",
"      - Bosutinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MONITORING DISEASE STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      AIMS OF INITIAL THERAPY AND DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36348\" title=\"table 1\">",
"      Risk score CML transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/56/3981\" title=\"table 2\">",
"      Response definitions CML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/58/12194?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_55_7035="GI defects causing hydrops";
var content_f6_55_7035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gastrointestinal abnormalities associated with hydrops fetalis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Volvulus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malrotation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duplication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meconium peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic vascular malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycystic disease of the liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7035=[""].join("\n");
var outline_f6_55_7035=null;
var title_f6_55_7036="Drugs causing tinnitus";
var content_f6_55_7036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some of the drugs that cause or exacerbate tinnitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Aminoglycoside antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin converting enzyme (ACE) inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimalarial drugs (eg, chloroquine, hydroxychloroquine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bismuth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlordiazepoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        COX-2 inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclobenzaprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxazosin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxepin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoroquinolone antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotretinoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine and other local anesthetics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loop diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroprusside",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prazosin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proton pump inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates and nonsteroidal antiinflammatory drugs (NSAIDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sibutramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tolbutamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproic acid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7036=[""].join("\n");
var outline_f6_55_7036=null;
var title_f6_55_7037="Infectious causes of cervical nodes";
var content_f6_55_7037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious causes of cervical lymphadenitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uncommon",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute bilateral",
"       </td>",
"       <td>",
"        <p>",
"         Rhinovirus",
"        </p>",
"        <p>",
"         Epstein-Barr virus*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Cytomegalovirus*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Herpes simplex virus",
"        </p>",
"        <p>",
"         Adenovirus",
"        </p>",
"        <p>",
"         Enterovirus",
"        </p>",
"        <p>",
"         <em>",
"          Mycoplasma pneumoniae",
"         </em>",
"        </p>",
"        <p>",
"         Group A streptococcus",
"        </p>",
"        <p>",
"         Influenza",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Roseola",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Parvovirus B19",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Corynebacterium diphtheriae",
"         </em>",
"        </p>",
"        <p>",
"         Rubella",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Measles",
"        </p>",
"        <p>",
"         Mumps",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute unilateral",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Staphylococcus aureus",
"         </em>",
"        </p>",
"        <p>",
"         Group A streptococcus",
"        </p>",
"        <p>",
"         Anaerobic bacteria",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Group B streptococcus",
"        </p>",
"        <p>",
"         Tularemia*",
"        </p>",
"        <p>",
"         Alpha streptococcus",
"        </p>",
"        <p>",
"         <em>",
"          Pasteurella multocida",
"         </em>",
"        </p>",
"        <p>",
"         <em>",
"          Yersinia pestis",
"         </em>",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Gram-negative bacilli",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Yersinia enterocolitia",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         Anthrax",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic unilateral",
"       </td>",
"       <td>",
"        <p>",
"         Nontuberculous",
"        </p>",
"        <p>",
"         <em>",
"          Mycobacterium",
"         </em>",
"        </p>",
"        <p>",
"         Cat scratch disease",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Toxoplasmosis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Tuberculosis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Actinomycosis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Nocardia brasiliensis",
"         </em>",
"        </p>",
"        <p>",
"         Aspergillosis",
"        </p>",
"        <p>",
"         Sporotrichosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic bilateral",
"       </td>",
"       <td>",
"        <p>",
"         Epstein-Barr virus",
"        </p>",
"        <p>",
"         Cytomegalovirus",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         HIV",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Toxoplasmosis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Tuberculosis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Syphilis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Brucellosis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Histoplasmosis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus.",
"     <br>",
"      * Infection can persist and become more chronic in appearance.",
"      <br>",
"       &bull; Often associated with generalized lymphadenopathy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7037=[""].join("\n");
var outline_f6_55_7037=null;
var title_f6_55_7038="Use of IFNa in chronic HBV";
var content_f6_55_7038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strategy for the treatment of HBeAg positive chronic HBV infection with interferon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 346px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * FDA approved dose and duration, a shorter duration of treatment may be sufficient.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7038=[""].join("\n");
var outline_f6_55_7038=null;
var title_f6_55_7039="Normal thromboelastography and parameters";
var content_f6_55_7039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Normal thromboelastography and parameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal citrated rapid TEG tracing with normal ACT, R time, K time, alpha angle, MA, G, and LY30.",
"    <div class=\"footnotes\">",
"     R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_55_7039=[""].join("\n");
var outline_f6_55_7039=null;
